RVTY Stifel maintains hold rating

Revvity (RVTY) Faces Neutral Sentiment from Analysts

Stifel maintained a 'Hold' rating on Revvity, Inc. (RVTY), a leading health sciences solutions provider, following a meeting with management. The investment firm set a price target of $110, reflecting cautious optimism. Artisan Partners, in its fourth-quarter 2025 investor letter, highlighted RVTY as an undervalued company with solid financial health and compelling business economics, indicating a positive long-term view.

The neutral sentiment from analysts is driven by Revvity's focus on translational multi-omics technologies and biomarker identification, which are promising but still in development stages. This cautious stance affects investors seeking immediate returns, particularly those focusing on mid-cap value stocks.

Upcoming catalysts include Revvity's next quarterly earnings report, scheduled for May 15, and any updates on the company's translational multi-omics technologies and biomarker identification efforts. These events will provide insights into Revvity's progress and potentially shift analyst sentiment.